Get started
Author

A. Chaudhry

Observed name: A Chaudhry
OpenAlex ID: A5112933539
Odronextamab in Patients With Relapsed/refractory Diffuse Large B‐cell Lymphoma (dlbcl): Results From a Prespecified Analysis of the Pivotal Phase Ii Study Elm‐2
2023 · M. Poon, J. Walewski, et al. · Hematological Oncology · 7
PDF
Odronextamab in Patients With Relapsed/refractory Follicular Lymphoma (fl) Grade 1–3a: Results From a Prespecified Analysis of the Pivotal Phase Ii Study Elm‐2
2023 · S. Novelli, S. Luminari, et al. · Hematological Oncology · 4
PDF
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”
2024 · T.M. Kim, M. Taszner, et al. · Annals of Oncology · 2
NovoTTFTM-100A System (Tumor Treating Fields) Transducer Array Layout Planning for Recurrent Glioblastoma: Results of a NovoTALTM System User Study
2015 · A. Chaudhry, L. Benson, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
PDF
1017eTiP A phase II trial of DB-1311/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305/BNT325 (TROP2 ADC) in advanced/metastatic solid tumors
2025 · Y. Guo, T.S. Gourdin, et al. · Annals of Oncology · 1
Clinical Responses to Odronextamab (regn1979): Correlation With Loss of Cd20 Expression as a Potential Mechanism of Resistance and Baseline Biomarkers of Tumor T Cells
2021 · J Brouwer‐Visser, N Fiaschi, et al. · Hematological Oncology · 1
PDF
Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study
2019 · W. Mansoor, E. Roeland, et al. · Annals of Oncology · 1
583 | Comparative Effectiveness of Odronextamab Versus Real‐world Systemic Therapies Used in an External Control Arm in Patients With Relapsed/refractory Follicular Lymphoma
2025 · E. Bachy, J. Harnett, et al. · Hematological Oncology
PDF
438 | Orelabrutinib for the Treatment of Relapsed/refractory Mantle Cell Lymphoma: Efficacy and Safety Results From a Global Phase 1/2 Study
2025 · Y. Wang, J. D'Olimpio, et al. · Hematological Oncology
PDF
424 | LONGITUDINAL TARGETED ctDNA ANALYSIS TO ASSESS CD20 and BAFF MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY FL OR DLBCL PROGRESSING ON ODRONEXTAMAB IN THE ELM‐2 STUDY
2025 · D. Tucker, J. E. Arnason, et al. · Hematological Oncology
PDF
242 | Long‐term Efficacy and Survival Outcomes With Odronextamab in Relapsed/refractory Follicular Lymphoma (r/r Fl): 2‐year Follow‐up From the Phase 2 Elm‐2 Study
2025 · S. Luminari, M. Taszner, et al. · Hematological Oncology
PDF
425 | Biomarker Analyses of the Inflammatory Profile and Mrd in Patients With Relapsed/refractory Marginal Zone Lymphoma Versus Follicular Lymphoma Treated With Odronextamab
2025 · E. Bachy, M. Taszner, et al. · Hematological Oncology
PDF
Trial in Progress: Odronextamab, a Cd20×cd3 Bispecific Antibody, for the Treatment of Relapsed/refractory Marginal Zone Lymphoma (r/r Mzl)—a Cohort From the Elm‐2 Study
2023 · S. Cho, T. M. Kim, et al. · Hematological Oncology
PDF
P1.13-30 Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor and its Relationship to NSCLC Patient Outcomes in the REVEL Trial
2018 · E. Garon, A. Tsao, et al. · Journal of Thoracic Oncology
Works count: 14
Citation count: 18
H-index: 2
I10-index:
Year
Topic
Type